Patient Choice Lifts Rheumatoid Arthritis Treatment Satisfaction

In a 102-patient trial, adults starting a first biologic-class drug reported higher satisfaction when they helped pick the treatment.

Updated on Nov. 3, 2026 in Arthritis

Bold flat-color editorial illustration of a smooth white oval tablet and a slim cylindrical injection pen side by side on a cream field.
A randomized trial of 102 new rheumatoid arthritis patients found those who helped choose their first biologic-class treatment reported higher satisfaction than those assigned one. AI Illustration. Upload story photo >

A multicenter randomized trial published October 27 in RMD Open found that rheumatoid arthritis patients who chose their own first biologic-class treatment reported higher satisfaction than those randomly assigned. The study compared a subcutaneous TNF inhibitor with the oral JAK inhibitor filgotinib in patients new to biologic therapy.

Why it matters

For people newly starting treatment for rheumatoid arthritis, the findings suggest that involvement in the choice of therapy may improve how well they tolerate and stay with it. The results are from a single trial of 102 patients, so they point to a direction worth discussing rather than a settled standard of care.

This multicenter randomized trial enrolled 102 biologic disease-modifying antirheumatic drug-naive rheumatoid arthritis patients and compared patient-choice with random assignment between a subcutaneous TNF inhibitor and filgotinib. Treatment satisfaction was significantly higher at 24 weeks in the patient-choice group, though the disease activity difference was not statistically significant.

The players

RMD Open

A peer-reviewed open-access journal that publishes research on rheumatic and musculoskeletal diseases, including arthritis.

Leeuwarden Medical Centre

A hospital in Leeuwarden, Netherlands, where the lead author practices and where rheumatology care for arthritis patients is delivered.

The details

In the patient-choice arm, participants picked between a weekly-style subcutaneous TNF inhibitor and the oral JAK inhibitor filgotinib, and most chose the pill. The randomized arm received the same treatment options without the choice. The randomized group used more glucocorticoids at week 12 and reported significantly more adverse events per patient, which the researchers linked to the differences seen in the patient-choice group.

Timeline

  1. Study published online October 27, 2026, in RMD Open.

  2. Fewer patient-choice participants had switched treatment mode by week 12.

  3. Treatment satisfaction was measured as significantly higher in the patient-choice group at week 24.

Health Landscape

Biologic and targeted therapies for rheumatoid arthritis now include both injected TNF inhibitors and oral JAK inhibitors, and clinicians increasingly weigh patient preference alongside efficacy and safety. This trial adds randomized evidence on how that preference-based choice compares with assigning treatment without input from the patient.

If you are weighing a first biologic-class treatment for rheumatoid arthritis, this trial suggests that having a say in the choice may be linked to higher satisfaction and better staying power with therapy. It is worth discussing with your rheumatologist which options fit your disease pattern, side-effect concerns, and daily routine.

The takeaway

Shared decision-making appears to matter for how patients experience rheumatoid arthritis treatment, not only which drug is prescribed. Ask your doctor how treatment options compare for your situation and what side effects to watch for.

Further reading

For broader context on how people live with joint inflammation, explore our Arthritis coverage.